{"id":547732,"date":"2025-10-15T00:00:00","date_gmt":"2025-10-15T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfid0003-2025-biopharma-human-immunodeficiency-virus-landscape-forecast-disease-landscape-forecast-g7\/"},"modified":"2026-03-31T10:24:38","modified_gmt":"2026-03-31T10:24:38","slug":"dlsfid0003-2025-biopharma-human-immunodeficiency-virus-landscape-forecast-disease-landscape-forecast-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfid0003-2025-biopharma-human-immunodeficiency-virus-landscape-forecast-disease-landscape-forecast-g7\/","title":{"rendered":"Human Immunodeficiency Virus &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>The <abbr data-abbreviation-entity=\"4843\" title=\"human immunodeficiency virus\">HIV<\/abbr> therapy market is undergoing significant transformation, driven by innovative <abbr data-abbreviation-entity=\"4995\" title=\"antiretroviral\">ARV<\/abbr>s and evolving treatment strategies. The market is crowded with many approved <abbr data-abbreviation-entity=\"4995\" title=\"antiretroviral\">ARV<\/abbr>s, including <abbr data-abbreviation-entity=\"5015\" title=\"single-tablet regimen\">STR<\/abbr>s such as Gilead\u2019s bictegravir \/ emtricitabine\/<abbr data-abbreviation-entity=\"5016\" title=\"tenofovir alafenamide\">TAF<\/abbr> (Biktarvy) and ViiV\u2019s dolutegravir \/ rilpivirine (Juluca) and dolutegravir\/lamivudine (Dovato), which offer improved safety, tolerability, and a lower long-term risk of comorbidities. Long-acting regimens have shown promising results in clinical trials, demonstrating effective viral suppression.Recent approvals of long-acting regimens such as ViiV\u2019s cabotegravir \/ rilpivirine (Cabenuva) and Gilead\u2019s lenacapavir (Sunlenca, targeting <abbr data-abbreviation-entity=\"4888\" title=\"multidrug-resistant\">MDR<\/abbr> <abbr data-abbreviation-entity=\"4843\" title=\"human immunodeficiency virus\">HIV<\/abbr> patients) have eliminated the need for lifelong daily pills, mitigating barriers to patient adherence. This report provides a detailed analysis of current medical practices, key unmet needs, and new developments in the <abbr data-abbreviation-entity=\"4843\" title=\"human immunodeficiency virus\">HIV<\/abbr> space, including oral long acting therapies, along with an analysis of the opportunities and obstacles facing emerging agents.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How large is the treatable <abbr data-abbreviation-entity=\"4843\" title=\"human immunodeficiency virus\">HIV<\/abbr> population, and how will diagnosis \/ drug-treatment rates change over time?<\/li>\n<li>What is the current state of <abbr data-abbreviation-entity=\"4843\" title=\"human immunodeficiency virus\">HIV<\/abbr> treatment? What are interviewed experts\u2019 insights into current treatments? What are the key unmet needs in <abbr data-abbreviation-entity=\"4843\" title=\"human immunodeficiency virus\">HIV<\/abbr>?<\/li>\n<li>What are <abbr data-abbreviation-entity=\"5534\" title=\"key opinion leader\">KOL<\/abbr>s\u2019 perceptions of key emerging therapies, and where do they see these agents fitting into the treatment algorithm?<\/li>\n<li>What factors drive and constrain the use of branded <abbr data-abbreviation-entity=\"5015\" title=\"single-tablet regimen\">STR<\/abbr>s and multi-tablet regimens in <abbr data-abbreviation-entity=\"4843\" title=\"human immunodeficiency virus\">HIV<\/abbr>? Which branded therapy is expected to experience the most commercial success during the forecast period?<\/li>\n<\/ul>\n<p><b>Geographies:<\/b> United States, <abbr data-abbreviation-entity=\"6092\" title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, Japan<\/p>\n<p><b>Primary research: <\/b>18 country-specific interviews with thought-leading infectious disease and internal medicine specialists supported by survey data collected for this and other Clarivate research.<\/p>\n<p><b>Epidemiology: <\/b>Number of diagnosed and drug-treated prevalent cases of <abbr data-abbreviation-entity=\"4843\" title=\"human immunodeficiency virus\">HIV<\/abbr> by country.<\/p>\n<p><b>Forecast: <\/b>10-year, annualized, drug-level sales and patient share of key <abbr data-abbreviation-entity=\"4843\" title=\"human immunodeficiency virus\">HIV<\/abbr> therapies through 2034, segmented by brands \/ generics and epidemiological subpopulations.<\/p>\n<p><b>Drug treatments: <\/b>Coverage of key current and late-phase emerging therapies.<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-547732","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-human-immunodeficiency-virus","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/547732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/547732\/revisions"}],"predecessor-version":[{"id":575309,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/547732\/revisions\/575309"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=547732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}